Effects of LDX on cognitive processes and appetite
Research type
Research Study
Full title
The effects of lisdexamfetamine dimesylate on cognitive, metabolic, and reward processes in individuals with binge-eating symptoms
IRAS ID
250510
Contact name
Elizabeth Schneider
Contact email
Sponsor organisation
University of Birmingham
Duration of Study in the UK
1 years, 0 months, 1 days
Research summary
This study will investigate the specific reward and cognitive mechanisms that underlie the effects of Lisdexamfetamine Dimesylate (LDX) on eating in people with binge-eating symptoms. LDX is a drug that has been approved for Attention-Deficit Hyperactivity Disorder, as well as the treatment of Binge Eating Disorder (BED). We will give both 50mg LDX and placebo to people with binge-eating symptoms on two separate days and measure LDX effects on appetite, food intake, and cognitive processes (e.g., inhibition, attention, memory). Appetite and food intake will be measured by eating in the absence of hunger, and cognitive processes will be measured using a variety of psychological/cognitive computer tests (e.g. memory tests). Participants will also undergo a brain imaging scan (fMRI) to determine the effects of LDX on brain function.
REC name
West Midlands - Solihull Research Ethics Committee
REC reference
18/WM/0360
Date of REC Opinion
9 Jan 2019
REC opinion
Further Information Favourable Opinion